UNASSIGNED: MicroRNAs are small single stranded molecules that play a crucial role in regulation of physiological and pathological processes. Recent studies showed that @entity5058 gene contains an highly evolutionary conserved binding site for mir-133. Moreover, in @entity1 hepatocytes mir-133 is constitutively co-expressed with @entity5058 . Since @entity5058 protein is the target of @entity1229 treatment, the aim of this study was to verify if genetic variations in @entity70476 , @entity19954 and @entity19953 could contribute to @entity1229 dose variability. By direct sequencing, we identified 4 SNPs in @entity19954 gene and 1 SNP in @entity19953 gene. Three SNPs in @entity19954 were in complete linkage disequilibrium and correlated with @entity1229 dose: indeed, for each SNP, @entity1 carrying the GA or AA genotype required a MWWD significantly higher than the wildtype genotype (P=0.019). We also inferred the haplotypes in @entity19954 gene. The GC haplotype required a MWWD significantly lower than AT haplotype (P=0.012). The multiple linear regression analysis confirmed that @entity70477 (as tag SNP) in @entity19954 could be involved in @entity1229 dosing variability, (P=0.016). These results seem to suggest that also polymorphisms in miRNA precursors may potentially affects drug response variability.

Could MicroRNA polymorphisms influence XXXX dosing? A pharmacogenetics study on mir133 genes.

@entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity70477 :: ('rs45547937', 'SNP') :: ['rs45547937'] @entity5058 :: ('79001', 'Gene') :: ['VKORC1'] @entity19954 :: ('406923', 'Gene') :: ['MIR133A2'] @entity70476 :: ('406922', 'Gene') :: ['MIR133A1'] @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin'] @entity19953 :: ('442890', 'Gene') :: ['MIR133B']
@entity1229 :: (MESH:D014859,Chemical) :: ['warfarin']
